Day 1: April 26, 2021

10:00-11:20 a.m.  | Session 1: Disease Progression from Precursor Conditions to Myeloma
10:00-10:05 a.m.   | Introduction
10:05-10:20 a.m.   | The genomic basis of smoldering multiple myeloma progression
Salomon Manier, University of Lille, Lille, France
10:20-10:35 a.m.   | Imaging-based predictors of disease progression in early stages of monoclonal plasma cell disorders
Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, NY
10:35-10:50 a.m.   | When to treat smoldering myeloma patients?
María-Victoria Mateos, University of Salamanca, Salamanca, Spain
10:50-11:20 a.m.   | Panel Discussion
Moderators: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MA, and Ola Landgren, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Panelists: Salomon Manier, Jens Hillengass, María-Victoria Mateos

11:20-11:35 a.m.   | Break

11:35 a.m.-12:55 p.m.  | Session 2: Genomics and Epigenetics of Myeloma
11:35 -11:40 a.m.   | Introduction
11:40-11:55 a.m.   | Understanding multiple myeloma life history using whole-genome sequencing
Francesco Maura, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
11:55 a.m.-12:10 p.m.   | Biological and therapeutic insights through CRISPR-based studies in myeloma
Constantine Mitsiades, Dana-Farber Cancer Institute, Boston, MA
12:10-12:25 p.m.  **The definition of high-risk myeloma**
Faith E. Davies, NYU Langone Health, New York, NY

12:25-12:55 p.m.  Panel Discussion

*Moderator: Brian Walker, Professor at Indiana University–Purdue University Indianapolis, Indianapolis, IN
Panelists: Faith E. Davies, Francesco Maura, Constantine Mitsiades*

**Day 2: April 27, 2021**

10:00-11:20 a.m.  **Session 3: Myeloma Microenvironment and Immunotherapy**

10:00-10:05 a.m.  Introduction

10:05-10:20 a.m.  **Emerging insights into immune microenvironment in myeloma**
Madhav V. Dhodapkar, Emory University, Atlanta, GA

10:20-10:35 a.m.  **Future advances in adoptive cellular therapy for MM**
Eric L. Smith, Dana-Farber Cancer Institute, Boston, MA

10:35-10:50 a.m.  **Updates in BiTes and CART: How do we choose the right patient?**
Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, NY

10:50-11:20 a.m.  Panel Discussion

*Moderators: Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA and Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA
Panelists: Madhav V. Dhodapkar, Eric L. Smith*

11:20-11:35 a.m.  Break

11:35 a.m.-12:55 p.m.  **Session 4: Novel Therapeutics and Drug Resistance**

11:35 -11:40 a.m.  Introduction

11:40-11:55 a.m.  **Targeting the BCL2 family in multiple myeloma**
Lawrence H. Boise, Emory Winship Cancer Institute, Atlanta, GA

11:55 a.m.-12:10 p.m.  **Targeted therapies in relapsed/refractory MM**
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany
12:10-12:25 p.m.  **Novel therapeutics and drug resistance treatment of lenalidomide refractory patients**  
Francesca Gay, University of Torino, Torino, Italy

12:25-12:55 p.m.  **Panel Discussion**  
*Moderators: Paola Neri, University of Calgary, Calgary, AB, Canada and Paula Rodríguez-Otero, University of Navarra, Pamplona, Spain*

*Panelists: Lawrence H. Boise, Francesca Gay, Paola Neri*

12:55-1:10 p.m.  **Break**

1:10-2:00 p.m.  **Panel Discussion**  
**Bench to Bedside – Application of Lessons Learned from COVID-19 to Clinical Trials and Drug Development in Myeloma**  
*Moderator: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA*

**Kenneth C. Anderson**

**Richard McDonald**

**Daniel Auclair**, Multiple Myeloma Research Foundation, Norwalk, CT

**Nicole J. Gormley**, FDA Center for Drug Evaluation & Research, Silver Spring, MD

**Craig L. Tendler**, Johnson & Johnson Pharmaceutical R&D, New Brunswick, NJ